$CDNA (CareDx, Inc) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 99.4%)

Graded daily on value C+, growth A, profitability B+, momentum A+, revisions A-. Sector-relative, identical for every user.

Most active credible voices on $CDNA

@stevedjacobs (Steve Jacobs) — 25 mentions · 17.0K followers
@equitydd (Equity investor) — 12 mentions · 11.3K followers
@cfromhertz (Christian Fromhertz 🇺🇸) — 9 mentions · 94.4K followers

Recent headlines featuring $CDNA

2026-09-27: Micron’s earnings day looms as Wall Street lifts price targets to $1,625

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $CDNA are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$CDNACareDx, Inc · Medical - Diagnostics & Research · $4.4B

$81.01

+0.3%

Event thread

Key events, in time order

11 items

2026-10-30EarningsBull
CareDx Q3 Earnings Beat, Revenue Up 39%
EPS $0.70 beats estimates, driven by testing volume growth and oncology addition
D1 +22.2% · +5d -10.1%
2026-10-308-K filing
8-K: Item 2.02, Item 7.01, Item 9.01
D1 +22.2% · +5d -10.1%

9 earlier events

2026-10-29Earnings
Earnings report
D1 -0.8% · +5d +6.7%
2026-10-22Product
CareDx Presents KOAR Data Linking Elevated AlloSure Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes
Company announcement highlights clinical data supporting AlloSure Kidney's prognostic value in borderline rejection or TCMR patients.
D1 -2.2% · +5d +3.4%
2026-09-178-K filing
8-K: Item 2.01, Item 9.01
D1 +1.4% · +5d +13.1%
2026-08-05Earnings
Earnings report
D1 -3.4% · +5d +4.0%
2026-07-31Earnings
CareDx Reports Q2 Earnings and Holds Conference Call
Company releases Q2 results, drawing market attention and stock rise.
D1 +14.7% · +5d +6.8%
2026-07-30Earnings
Earnings report
非 GAAP 毛利率提升至 74%，调整后 EBITDA 增长 $19 百万至 $25 百万，占营收 19%。
D1 +7.6% · +5d +17.6%
2026-07-308-K filing
8-K: Item 2.02, Item 7.01, Item 9.01
D1 +7.6% · +5d +17.6%
2026-07-16RegulationBull
Medicare Finalizes Coverage for CareDx Transplant Molecular Tests
Final LCD coverage decision affects reimbursement for core transplant diagnostics
D1 +35.6% · +5d -6.8%
2026-07-16Earnings
CareDx to Report Q2 2026 Results on July 30
Company announces earnings date; market awaits results and volume trends
D1 +35.6% · +5d -6.8%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

11 items

2026-10-30EarningsBull
CareDx Q3 Earnings Beat, Revenue Up 39%
EPS $0.70 beats estimates, driven by testing volume growth and oncology addition
D1 +22.2% · +5d -10.1%
2026-10-308-K filing
8-K: Item 2.02, Item 7.01, Item 9.01
D1 +22.2% · +5d -10.1%
2026-10-29Earnings
Earnings report
D1 -0.8% · +5d +6.7%
2026-10-22Product
CareDx Presents KOAR Data Linking Elevated AlloSure Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes
Company announcement highlights clinical data supporting AlloSure Kidney's prognostic value in borderline rejection or TCMR patients.
D1 -2.2% · +5d +3.4%
2026-09-178-K filing
8-K: Item 2.01, Item 9.01
D1 +1.4% · +5d +13.1%

6 earlier events

2026-08-05Earnings
Earnings report
D1 -3.4% · +5d +4.0%
2026-07-31Earnings
CareDx Reports Q2 Earnings and Holds Conference Call
Company releases Q2 results, drawing market attention and stock rise.
D1 +14.7% · +5d +6.8%
2026-07-30Earnings
Earnings report
非 GAAP 毛利率提升至 74%，调整后 EBITDA 增长 $19 百万至 $25 百万，占营收 19%。
D1 +7.6% · +5d +17.6%
2026-07-308-K filing
8-K: Item 2.02, Item 7.01, Item 9.01
D1 +7.6% · +5d +17.6%
2026-07-16RegulationBull
Medicare Finalizes Coverage for CareDx Transplant Molecular Tests
Final LCD coverage decision affects reimbursement for core transplant diagnostics
D1 +35.6% · +5d -6.8%
2026-07-16Earnings
CareDx to Report Q2 2026 Results on July 30
Company announces earnings date; market awaits results and volume trends
D1 +35.6% · +5d -6.8%

$CDNA — what investors on X are saying · SpikePanel

$CDNA (CareDx, Inc) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 99.4%)

Most active credible voices on $CDNA

Recent headlines featuring $CDNA

$CDNA (CareDx, Inc) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 99.4%)

Most active credible voices on $CDNA

Recent headlines featuring $CDNA

CareDx Q3 Earnings Beat, Revenue Up 39%

8-K: Item 2.02, Item 7.01, Item 9.01

Earnings report

CareDx Presents KOAR Data Linking Elevated AlloSure Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes

8-K: Item 2.01, Item 9.01

Earnings report

CareDx Reports Q2 Earnings and Holds Conference Call

Earnings report

8-K: Item 2.02, Item 7.01, Item 9.01

Medicare Finalizes Coverage for CareDx Transplant Molecular Tests

CareDx to Report Q2 2026 Results on July 30

Bull vs bear

Discussion

CareDx Q3 Earnings Beat, Revenue Up 39%

8-K: Item 2.02, Item 7.01, Item 9.01

Earnings report

CareDx Presents KOAR Data Linking Elevated AlloSure Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes

8-K: Item 2.01, Item 9.01

Earnings report

CareDx Reports Q2 Earnings and Holds Conference Call

Earnings report

8-K: Item 2.02, Item 7.01, Item 9.01

Medicare Finalizes Coverage for CareDx Transplant Molecular Tests

CareDx to Report Q2 2026 Results on July 30